The Drug Enforcement Administration (DEA) will commence a hearing on June 29, 2026, to review marijuana's classification. This follows the Trump Administration’s move to reclassify medical marijuana to Schedule III under the Controlled Substances Act. Trulieve Cannabis Corp. has already filed for DEA registration for its retail locations.
Rescheduling could eliminate the 280E tax burden. This federal rule currently prevents cannabis companies from deducting ordinary business expenses.
The policy shift would improve profitability and cash flow for operators like Trulieve. Investors view the hearing as a critical milestone for the U.S. cannabis industry.